北京鞍石生物科技

Anshi Pharma (Beijing Anshi Biotechnology) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology, particularly targeting precision medicine pathways. The company's lead product, vebreltinib (Bozitinib), is a potent and selective MET inhibitor that has received conditional approval in China for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Anshi Pharma maintains a robust pipeline of small molecules and biologics targeting various oncogenic drivers, including E-selectin and PD-1. The company operates as the primary Chinese subsidiary of Apollomics, leveraging global R&D capabilities to address unmet medical needs in cancer treatment. With facilities in Beijing and Hangzhou, Anshi Pharma is well-positioned to advance its candidates through clinical development and commercialization in the Asia-Pacific region and beyond.